Prostate Cancer VL

Prostate Cancer Screening is a Shared Decision - Matthew Cooperberg

Details
Alicia Morgans and Matt Cooperberg discuss the controversial topic of how to optimally screen for prostate cancer based on the final recommendations from the U.S. Preventive Services Task Force. Biographies: Matthew Cooperberg, MD, MPH, FACS, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH Further Related Content: Biomarker Debate: Adopt, Expand, Trust (PRO) HPFS Healt...

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer - Daniel Spratt

Details
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Biographies: Daniel Spratt, MD, Assistant Professor, Vice Chair, Clinical Research Chair, Division of Genitourinary Clinical Research Chief, Genitourinary Radiotherapy Program Department of Radiation Oncology, University of Michigan. Alicia Morgans, MD, MPH Ref...

Personal Prostate Cancer Journey to Raise Funds and Awareness- Sanford Siegel

Details
(Length of Discussion: 4 min) Dr. Sanford J. Siegel, CEO of Chesapeake Urology, has always been an advocate and supporter of prostate cancer screening in men, especially those at high risk. Since 2006, under his leadership, Chesapeake Urology has provided free screenings to Maryland men, mostly in Baltimore City. In this video, Dr. Siegel shares his own prostate cancer story. Biographies: Sanford...

Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens - E. David Crawford

Details
(Length of Presentation: 20 min) Neal Shore, MD, FACS interviews E. David Crawford on a forthcoming paper he authored titled, A ndrogen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Anti-androgens . This paper takes the historical approach in reviewing the treatment of prostate cancer, where we started in the 60's, where we are today and where we hope to be in the futur...

Screening for Prostate Cancer in African American Men - Judd Moul

Details
Prostate cancer in African-American men remains a major public health issue. Judd W Moul, MD, reviews the history of the U.S. Preventive Services Task Force screening guidelines and highlights the US trends and patterns of disparities in cancer mortality among U.S. counties from 1980 to 2014. He touches on the molecular differences that may explain, in part, the aggressiveness of prostate cancer i...

The United States Preventive Services Task Force PSA Screening Recommendations- David Penson

Details
(Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...

Novel Circulating Tumor Cells Blood Assay for the Clarification of 4-10 ng/mL PSA Results - See-Tong Pang

Details
(Length of Discussion: 15 min) Tom Keane and See-Tong Pang discuss the results of a prospective clinical study utilizing a novel circulating tumor cells (CTC) blood assay to clarify PSA results in 200 men who present with a PSA of 4ng/ml-10ng/ml. The CellMax CTC Platform is used to isolate CTCs to assess NPV and PPV for Gray Zone patients. Isolated CTCs may also be analyzed for the presence of pro...

Optimizing Care in Patients with High Risk Prostate Cancer - Interview with Edward Schaeffer

Details
(Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...

Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb

Details
(Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...

Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng

Details
Felix Feng, MD talks with Alicia Morgans, MD, MPH on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up front. In addition, they also dis...